Shane Olwill Net Worth

The estimated Net Worth of Shane Olwill is at least $753 mil dollars as of 30 August 2021. Shane Olwill owns over 38,400 units of Pieris Pharmaceuticals Inc stock worth over $752,735 and over the last 3 years he sold PIRS stock worth over $0. In addition, he makes $0 as Senior Vice President - Head of Translational Science at Pieris Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Shane Olwill PIRS stock SEC Form 4 insiders trading

Shane has made over 1 trades of the Pieris Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 38,400 units of PIRS stock worth $58,368 on 30 August 2021.

The largest trade he's ever made was exercising 38,400 units of Pieris Pharmaceuticals Inc stock on 30 August 2021 worth over $58,368. On average, Shane trades about 12,800 units every 0 days since 2021. As of 30 August 2021 he still owns at least 43,038 units of Pieris Pharmaceuticals Inc stock.

You can see the complete history of Shane Olwill stock trades at the bottom of the page.

Shane Olwill biography

Dr. Shane Olwill Ph.D. serves as Senior Vice President - Head of Translational Science of the Company. Dr. Shane Olwill has spent over a decade in oncology focused drug discovery with a specific interest in the development of novel biologics. Prior to joining Pieris, Shane was Director of Research at Fusion Antibodies Ltd where he was responsible for the discovery and development of multiple drug candidates. He is a named inventor on 16 patents and has published his research in many international peer review journals. Shane received his PhD in Molecular Hematology / Oncology from University of Ulster, following which he worked as an industrial postdoc in conjunction with University College Cork. Shane has a PgDip in Management Practice from DIT Business School and is a state qualified Medical Scientist.

What's Shane Olwill's mailing address?

Shane's mailing address filed with the SEC is C/O PIERIS PHARMACEUTICALS, INC., 225 FRANKLIN STREET, 26TH FLOOR, BOSTON, MA, 02110.

Insiders trading at Pieris Pharmaceuticals Inc

Over the last 9 years, insiders at Pieris Pharmaceuticals Inc have traded over $24,745,707 worth of Pieris Pharmaceuticals Inc stock and bought 1,154,000 units worth $3,376,410 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Advisors Llc Orbi Med Capit... y Chau Quang Khuong. On average, Pieris Pharmaceuticals Inc executives and independent directors trade stock every 144 days with the average trade being worth of $4,572,148. The most recent stock trade was executed by Capital Management, Llcadar... on 9 August 2024, trading 6,000 units of PIRS stock currently worth $92,340.

What does Pieris Pharmaceuticals Inc do?

pieris pharmaceuticals is a clinical stage biotechnology company that discovers and develops anticalin-based drugs to target validated disease pathways in a unique and transformative way. our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled anticalin to treat uncontrolled asthma and a half-life-optimized anticalin to treat anemia. proprietary to pieris, anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. our libraries of more than 100 billion different anticalin proteins have repeatedly delivered drug candidates binding to a very broad spectrum of therapeutic targets. pieris has established a diverse pipeline of anticalin therapeutics for a number of different indications and has r&d collaborations with roche

Complete history of Shane Olwill stock trades at Pieris Pharmaceuticals Inc

Pieris Pharmaceuticals Inc executives and stock owners

Pieris Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Stephen Yoder,
  President, Chief Executive Officer, Director
• Hitto Kaufmann,
  Senior Vice President, Chief Scientific Officer
• Stephen S. Yoder J.D.,
  CEO, Pres & Director
• Stephen S. Yoder,
  CEO, Pres & Director
• Dr. Hitto Kaufmann Ph.D.,
  Sr. VP & Chief Scientific Officer
• Dr. Tim Demuth M.D., Ph.D.,
  Sr. VP & Chief Medical Officer
• Thomas Bures,
  Sr. VP & CFO
• james Geraghty,
  Independent Chairman of the Board
• Christopher Kiritsy,
  Independent Director
• Peter Kiener,
  Independent Director
• Matthew Sherman,
  Independent Director
• Michael Richman,
  Independent Director
• Ann Barbier,
  Independent Director
• Maya Said,
  Independent Director
• Maria Kelman,
  Director of Investor Relations
• Shane Olwill,
  Senior Vice President - Head of Translational Science
• Eckhard Niemeier,
  Senior Vice President - Head of Business Development
• Ingmar Bruns,
  Senior Vice President - Head of Clinical Development
• Ahmed Mousa,
  Senior Vice President - Corporate Operations , General Counsel, Secretary
• Thomas Bures,
  Chief Financial Officer, Principal Accounting Officer, Vice President - Finance, Treasurer
• Dr. Shane Olwill Ph.D.,
  Sr. VP & Chief Devel. Officer
• Ahmed S. Mousa J.D.,
  Sr. VP, Chief Bus. Officer, Gen. Counsel & Corp. Sec.
• Prompong Chaikul,
  Chief Supply Chain Officer
• Dr. Christine Rothe,
  Head of Discovery & Alliance Management and VP
• Frank Vollmering,
  VP of HR
• Advisors Llc Orbi Med Capit...,
  
• Jean Pierre Bizzari,
  
• Claude Knopf,
  Chief Business Officer
• Steven Prelack,
  Director
• Julian Adams,
  
• Louis Matis,
  SVP, Chief Development Officer
• Darlene M Deptula Hicks,
  Sr. Vice President and CFO
• Chau Quang Khuong,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Allan Reine,
  Chief Financial Officer
• Partners L P/Ilbiotechnolog...,
  
• Capital Management, Llc Aquilo,
  10% owner
• Tim Demuth,
  Chief Medical Officer
• Capital Management, Llcadar...,